Rationale and design of a secondary prevention trial of lowering normal plasma cholesterol levels after acute myocardial infarction: The cholesterol and recurrent events trial (CARE)-Reference-Cited by-同舟云学术

Rationale and design of a secondary prevention trial of lowering normal plasma cholesterol levels after acute myocardial infarction: The cholesterol and recurrent events trial (CARE)

Published:1991-12 Issue:15 Volume:68 Page:1436-1446
ISSN:0002-9149
Container-title:The American Journal of Cardiology
language:en
Short-container-title:The American Journal of Cardiology

Author:

Sacks Frank M.,Pfeffer Marc A.,Moye' Lemuel,Brown Lisa E.,Hamm Peggy,Cole Thomas G.,Hawkins C.Morton,Braunwald Eugene,The CARE Investigators

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference35 articles.

1. Seven Countries Study;Keys,1980

2. Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease;Pekkanen;N Engl J Med,1990

3. Cholesterol in the prediction of atherosclerotic disease. New perspectives on the Framingham Study;Kannel;Ann Intern Med,1979

4. Serum cholesterol, blood pressure, and mortality: implications from a cohort of 361,662 men;Martin;Lancet,1986

5. Myocardial ischemia, risk factors and death from coronary heart-disease;Rose;Lancet,1977

Cited by 111 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis;Cochrane Database of Systematic Reviews;2023-11-29

2. Pharmacological interventions for heart failure in people with chronic kidney disease;Cochrane Database of Systematic Reviews;2020-02-27

3. Proprotein Convertase Subtilisin-Kexin Type 9 (PCSK9) Inhibitors and Cardiovascular Risk: Does a Further Analysis of the Fourier Trial Suggest Changes in the Target of Lipid Lowering Therapy?;High Blood Pressure & Cardiovascular Prevention;2018-01-05

4. Pravastatin: A First Generation HMG CoA Reductase Inhibitor ☆;Reference Module in Biomedical Sciences;2018

5. Traitement de l'infarctus du myocarde avec sus-décalage du segment ST;Pharmacie Clinique et Thérapeutique;2018